Literature DB >> 1673654

Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis.

H Koop1, R Arnold.   

Abstract

Thirty-four patients with H2-blocker-resistant reflux esophagitis subsequently healed by 40 mg omeprazole daily entered a maintenance study with 20 mg omeprazole. In 31 evaluable cases the observation period was at least 12 months (mean 24 months). Esophagitis remained in remission in two thirds of patients despite dose reduction. Relapses of esophagitis occurred in 10 cases within six months, which rapidly healed by increasing the omeprazole dose to 40 mg. No further recurrence with 20 mg omeprazole was found later than six months. Peptic strictures primarily requiring repeated dilatation in six patients during healing with omeprazole did not reappear while on omeprazole maintenance. Major side effects that could be attributed to omeprazole were not observed. Gastrin levels remained within or slightly above the normal range in the vast majority. It is concluded that omeprazole maintenance treatment in severe reflux esophagitis is an effective and safe therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673654     DOI: 10.1007/bf01297018

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

Review 1.  Treatment of reflux oesophagitis resistant to H2-receptor antagonists.

Authors:  E C Klinkenberg-Knol; S G Meuwissen
Journal:  Digestion       Date:  1989       Impact factor: 3.216

Review 2.  Histopathological classification of nonantral gastric endocrine growths in man.

Authors:  E Solcia; C Bordi; W Creutzfeldt; Y Dayal; A D Dayan; S Falkmer; L Grimelius; N Havu
Journal:  Digestion       Date:  1988       Impact factor: 3.216

3.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole.

Authors:  D J Hetzel; J Dent; W D Reed; F M Narielvala; M Mackinnon; J H McCarthy; B Mitchell; B R Beveridge; B H Laurence; G G Gibson
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

4.  [Therapy and prevention of reflux esophagitis. Results of a multicenter study with cimetidine. I: Epidemiology and results of acute therapy].

Authors:  J R Siewert; R Ottenjann; K Heilmann; A Neiss; H Döpfer
Journal:  Z Gastroenterol       Date:  1986-08       Impact factor: 2.000

5.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

6.  [Different healing tendencies of reflux esophagitis following omeprazole and ranitidine. Results of a German-Austrian-Swiss multicenter study].

Authors:  H G Dammann; A L Blum; G Lux; M Rehner; E O Riecken; R Schiessel; M Wienbeck; L Witzel; J Berger
Journal:  Dtsch Med Wochenschr       Date:  1986-01-24       Impact factor: 0.628

7.  Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis.

Authors:  G Vantrappen; L Rutgeerts; P Schurmans; J L Coenegrachts
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

8.  Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2-receptor-antagonist-resistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output.

Authors:  E C Klinkenberg-Knol; J B Jansen; C B Lamers; F Nelis; S G Meuwissen
Journal:  Scand J Gastroenterol       Date:  1990-11       Impact factor: 2.423

Review 9.  Omeprazole in the short-term treatment of reflux oesophagitis.

Authors:  J B Jansen; C B Lamers
Journal:  Digestion       Date:  1989       Impact factor: 3.216

10.  Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial.

Authors:  T Havelund; L S Laursen; E Skoubo-Kristensen; B N Andersen; S A Pedersen; K B Jensen; C Fenger; F Hanberg-Sørensen; K Lauritsen
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09
View more
  16 in total

1.  Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia.

Authors:  Pankaj Singh; Anant Indaram; Ronald Greenberg; Vernu Visvalingam; Simmy Bank
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Oesophageal mucosal diseases in the elderly.

Authors:  R Ouatu-Lascar; G Triadafilopoulos
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

Review 3.  Chronic proton pump inihibitor therapy and calcium metabolism.

Authors:  Yu-Xiao Yang
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 4.  Safety of potent gastric acid inhibition.

Authors:  Carlos Martín de Argila
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Lansoprazole for maintenance of remission of erosive oesophagitis.

Authors:  James W Freston; Robert L Jackson; Bidan Huang; E David Ballard
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole.

Authors:  D Gillen; A A Wirz; W D Neithercut; J E Ardill; K E McColl
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

7.  Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds.

Authors:  E Verdu; F Viani; D Armstrong; R Fraser; H H Siegrist; B Pignatelli; J P Idström; C Cederberg; A L Blum; M Fried
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

Review 8.  Pathophysiological effects of long-term acid suppression in man.

Authors:  R F McCloy; R Arnold; K D Bardhan; D Cattan; E Klinkenberg-Knol; P N Maton; R H Riddell; P Sipponen; A Walan
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 9.  Pharmacological management of gastro-oesophageal reflux disease.

Authors:  E C Klinkenberg-Knol; H P Festen; S G Meuwissen
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 10.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.